Abstract Details Title Effectiveness of epilepsy treatment with Cannabis Sativa derivatives in children with Dravet Syndrome – Systematic Review Topic Epilepsy/Clinical Neurophysiology (EEG) Presentation(s) P1 - Poster Session 1 (9:00 AM-5:00 PM) Poster/Presentation Number 147 Objective To verify the evidences presented on literature about the effectiveness of Cannabis sativa derivatives: Tetrahydrocannabinol (THC) and Cannabidiol (CBD) for epilepsy control in pediatric patients with Dravet's Syndrome. Background Dravet's Syndrome consists on a rare refractory epilepsy of genetic origin, which affects children from the first year of life and causes neurodevelopment changes. The standard treatment includes different anticonvulsants, which do not completely stop the attacks; so the search for drugs that have a greater possibility of the attacks controlling has been the focus of several studies. Design/Methods This is a systematic review and searches were performed on the PubMed, LILACS and SciELO databases, using the descriptors (DeCS), "Epilepsy", "Treatment", "Dravet Syndrome", "Cannabinoids". Randomized clinical trials, published in the last 10 years, in English, Spanish or Portuguese languages and involving individuals up to 18 years of age were included. Studies without a summary were excluded. Methodological quality was assessed using the CONSORT scale. Results There were 92 articles identified at start; 3 were included in the analysis, in a total sample of 352 children with Dravet's Syndrome. There was a predominance of girls. The reduction in the seizures frequency during treatment was at least 50% of the baseline, for the total of children in the CBD groups (221 individuals), ranging from 43 to 56.4%. Conclusions The present Systematic Review showed that in the three studies there was a frequency reduction of seizures for children using use of CBD. It was not possible to evaluate THC because no studies were found that met the inclusion criteria. The paraffects (reported above as associated with the use of CBD) did not compromise the CBD positive evaluation in all articles studied. As a rare syndrome and because substances derived from Cannabis sativa involve social stigmas, the studies present samples size limitations. Authors/Disclosures PRESENTER No disclosure on file No disclosure on file